HK Stock Market Move | CARDIOFLOW-B (02160) issued a profit warning, with a close to 3% increase in opening. It is expected that the net loss in 2024 will decrease by about 87% to 94% compared to the previous year.

CARDIOFLOW-B (02160) issued a profit warning with a high opening of nearly 3%, as of press time, it rose 2.4% to 1.28 Hong Kong dollars, with a turnover of 405,800 Hong Kong dollars. On the news front, on March 6, CARDIOFLOW-B announced that the group expects to incur a net loss of approximately RMB 30-60 million in 2024, a decrease of approximately 87% to 94% year-on-year. The announcement stated that the expected reduction in loss is mainly due to the orderly promotion of the commercialization of VitaFlow and VitaFlow Liberty transcatheter aortic valve implantation products and the AnchorMan left atrial appendage occluder system and its guiding system in China, with a continuous increase in implantation volume; VitaFlow Liberty transcatheter aortic valve and retrievable delivery system obtained CE marking during the reporting period and has been sold in more than 17 countries/regions overseas, with revenue from overseas increasing by more than double compared to 2023.